ReviewTrends in microbiology2026
Molecular pathways linking the gut microbiome to antitumor immunity.
Review in Trends in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Accumulating evidence supports the important role played by the gut microbiota in controlling antitumor immune responses that impact tumor development. Extensive studies of bacterial species known to impact tumor growth have identified metabolites, produced by either bacteria or the host, that may alter efficacy of chemo- and/or immune-based therapies. Here, we summarize our current knowledge of those metabolites and the related bacterial species that influence activities linked with antitumor immunity, including epigenetic changes, the aryl hydrocarbon receptor signaling, cytokine and chemokine production, Janus kinase/signal transducer and activator of transcription signaling, and toll-like receptor signaling. We focus on specific metabolites, produced in the gut microbiome, which can alter molecular pathways associated with antitumor immunity, findings that warrant further evaluation in preclinical or clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.